Development and Validation of a Novel Machine Learning Model to Predict the Survival of Patients with Gastrointestinal Neuroendocrine Neoplasms
Authors:
- Si LiuSLSi Liu
- Yun-Xiang ChenYCYun-Xiang Chen
- Bing DaiBDBing Dai
- Li ChenLCLi Chen
- 6 May 2024
- journal article
- research article
- Published by S. Karger AG in Neuroendocrinology
- Vol. 114 (8) , 733-748
Abstract
Introduction: Well-calibrated models for personalized prognostication of patients with gastrointestinal neuroendocrine neoplasms (GINENs) are limited. This study aimed to develop and validate a machine-learning model to predict the survival of patients with GINENs. Methods: Oblique random survival forest (ORSF) model, Cox proportional hazard risk model, Cox model with least absolute shrinkage and selection operator penalization, CoxBoost, Survival Gradient Boosting Machine, Extreme Gradient Boosting survival regression, DeepHit, DeepSurv, DNNSurv, logistic-hazard model, and PC-hazard model were compared. We further tuned hyperparameters and selected variables for the best-performing ORSF. Then, the final ORSF model was validated. Results: A total of 43,444 patients with GINENs were included. The median (interquartile range) survival time was 53 (19–102) months. The ORSF model performed best, in which age, histology, M stage, tumor size, primary tumor site, sex, tumor number, surgery, lymph nodes removed, N stage, race, and grade were ranked as important variables. However, chemotherapy and radiotherapy were not necessary for the ORSF model. The ORSF model had an overall C index of 0.86 (95% confidence interval, 0.85–0.87). The area under the receiver operation curves at 1, 3, 5, and 10 years were 0.91, 0.89, 0.87, and 0.80, respectively. The decision curve analysis showed superior clinical usefulness of the ORSF model than the American Joint Committee on Cancer Stage. A nomogram and an online tool were given. Conclusion: The machine learning ORSF model could precisely predict the survival of patients with GINENs, with the ability to identify patients at high risk for death and probably guide clinical practice.Keywords
This publication has 54 references indexed in Scilit:
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An UpdateCurrent Oncology Reports, 2024
- Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2Journal of Gastroenterology, 2023
- Surgical Management of the Primary Tumor in Stage IV Small Intestinal Neuroendocrine Tumors: To Operate or Not to Operate, That Is the QuestionCurrent Oncology Reports, 2023
- JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsisJournal of Gastroenterology, 2021
- Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United StatesJAMA Network Open, 2021
- Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 studyCancer, 2020
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approachStatistics in Medicine, 2014
- TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2007
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006